Evaluating the Pharmacokinetics and Safety of Miricorilant
Abroad (travel likely)RecruitingPHASE1
Conditions
Nonalcoholic Steatohepatitis (NASH) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-alcoholic Fatty Liver Disease (NAFLD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Site# 433, San Antonio, Texas, United States
Study leads
Aprille Espinueva, PharmD
Study Director
Corcept Therapeutics